Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 1;146(3):968–976. doi: 10.1093/brain/awac357

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the Guarantors of Brain 2022.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Immunomodulation results in decreases in antigen specific antibodies. (A) Serum antibodies to O. volvulus antigen-16 (Ov16) or (B) O. volvulus tropomyosin (OVTmy1) in two patients prior to (black bars) and after (grey bars) plasmapheresis. Total IgG antibodies specific for O. volvulus antigens are shown on the left and IgG4 antibodies are shown on the right. (C) Serum antibodies to OV16 (IgG and IgG4) and OVTmy1 (IgG and IgG4) in a patient prior to (black bars) and after (grey bars) administration of intravenous immunoglobulin (IVIg).